Wills Eye Retina specialists are in the forefront of research efforts, participating in multiple retina studies to investigate new forms of treatment for macular degeneration, diabetic retinopathy, and a variety of other retinal conditions. We are committed to providing access to new treatments and have been the principal investigators of most of the major retina studies. For several, we are the only center involved nationwide.
For more information about our
Retina Study,
call 267-541-3016
Longer-Acting Pharmacologic Agents: These new medical compounds are being studied to determine their efficacy and safety in comparison to the current standard anti-vascular endothelial growth factor (VEGF) agents. Administered by intravitreal injection, they may potentially achieve a longer therapeutic effect.
Genentech/Roche (AVONELLE-X)
A study to evaluate the long-term safety and tolerability of Faricimab in patients with neovascular (wet) age-related macular degeneration.
Learn more.
Regeneron (PULSAR)
A study to evaluate the efficacy and safety of high dose Aflibercept in Patients with neovascular (wet) age-related macular degeneration.
Learn more.
Opthea (COAST)
A study to evaluate the efficacy and safety of intravitreal OPT-302 in combination with Aflibercept, compared with Aflibercept alone, in participants with neovascular (wet) age-related macular degeneration.
Learn more.
Eyepoint (EYP-1901)*
A study to evaluate the safety and efficacy of EYP-1901, a tyrosine kinase inhibitor (TKI), compared to Aflibercept in subjects with neovascular (wet) age-related macular degeneration.
Learn more.
*pending
Unity Biotechnology, Inc. (UBX1325)
A study to evaluate the safety, tolerability, and evidence of activity of a repeated intravitreal injection of UBX1325 in patients with neovascular (wet) age-related macular degeneration.
Learn more.
Port Delivery System (PDS): PDS is a small surgical implant that is intended to slowly release ranibizumab, a well-established anti-VEGF medication. The aim is to reduce the need for intravitreal injections and the implant can be refilled with a special syringe in the office setting.
Roche /Genentech (BURGUNDY)
A study to investigate the safety, tolerability, pharmacokinetics, and efficacy of RO7250284 following intravitreal administration of multiple ascending doses and sustained delivery from the port delivery system in patients with neovascular (wet) age-related macular degeneration.
Learn more.
Gene Therapy: These technologies utilize different non-disease-causing viral vectors to carry and deliver a coding sequence for a soluble anti-VEGF protein. In essence, the goal is for anti-VEGF medication to be manufactured by cells in the eye, which will hopefully reduce the need for frequent intravitreal injections.
Adverum Biotechnologies (LUNA)*
A study to assess safety and efficacy of an intravitreal injection of ADVM-022 (AAV.7m8-Aflibercept) in anti-VEGF treatment experienced patients with neovascular (wet) age-related macular degeneration.
Learn more.
Regenxbio (ATMOSPHERE)
A study to evaluate the efficacy and safety of RGX-314 gene therapy in participants with neovascular (wet) age-related macular degeneration.
Learn more.
*pending
Regenexbio (AAVIATE)
A study to evaluate the efficacy, safety, and tolerability of RGX-314 gene therapy delivered via one or two suprachoroidal space (SCS) injections in participants with neovascular (wet) age-related macular degeneration.
Learn more.
Regenexbio (RGX-314 Gene Therapy)
A study to explore the pharmacodynamics of two doses in two formulations of RGX-314 gene therapy administered via subretinal delivery in participants with neovascular (wet) age-related macular degeneration.
Learn more.
For more information about our
Retina Study,
call 267-541-3016
Anti-Inflammation: Inflammation is implicated in the pathophysiology of atrophy and vision cell loss in advanced dry AMD. Pharmacologic agents designed to block or modulate various parts of the inflammation process may slow the progression and development of geographic atrophy.
Alexion (ALXN2040)
A study of Danicopan (ALXN2040) in patients with geographic atrophy (GA) secondary to age-related macular degeneration).
Learn more.
Apellis (GALE)
A study to evaluate the long-term safety and efficacy of Pegcetacoplan in subjects with geographic atrophy secondary to age-related macular degeneration.
Learn more.
Annexon(ARCHER)
A study of the efficacy, safety and tolerability of ANX007 administered by intravitreal injection in patients with geographic atrophy secondary to age-related macular degeneration.
Learn more.
NGM Biopharmaceuticals (CATALINA)
A study of the safety and efficacy of intravitreal injections of NGM621 in subjects with geographic atrophy secondary to age-related macular degeneration.
Learn more.
Gene Therapy: These technologies utilize different non-disease-causing viral vectors to carry and deliver a coding sequence for anti-inflammatory proteins. In essence the goal is for anti-inflammatory medication to be manufactured by cells in the eye, which will hopefully reduce the need for frequent intravitreal injections.
Gyroscope (HORIZON)
A study to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with geographic atrophy secondary to dry age-related macular degeneration.
Learn more.
Gyroscope (FOCUS)
A study to evaluate the safety, safety and dose-response of GT005 administered as a single subretinal injection in subjects with macular atrophy due to age-related macular degeneration.
Learn more.
Cell Based: Cell-based therapy involves the subretinal surgical delivery of stem cells to replace or regenerate dysfunctional cells and tissue caused by dry AMD.
Lineage Cell Therapeutics (BIOTIME)(OPREGEN)
A study of the safety and efficacy of human embryonic stem cell-derived retinal pigment epithelial cells transplanted subretinally in patients with advanced age-related macular degeneration (geographic atrophy).
Learn more.
Longer-Acting Pharmacologic Agents: These new medical compounds are being studied to determine their efficacy and safety in comparison to the current standard anti-vascular endothelial growth factor (VEGF) agents. Administered by intravitreal injection, they may potentially achieve a longer therapeutic effect.
Roche/Genentech (RHONE-X)
A study to evaluate the long-term safety and tolerability of Faricimab in patients with diabetic macular edema.
Learn more.
Kodiak (GLEAM)
A study to evaluate the efficacy and safety of intravitreal KSI-301 compared with intravitreal Aflibercept in participants with visual impairment secondary to diabetic macular edema.
Learn more.
Roche/Genentech (ELEVATUM)
A study to evaluate Faricimab (RO6867461) treatment response in treatment-naive, underrepresented patients with diabetic macular edema.
Learn more.
Regeneron (PHOTON)
A study of the efficacy and safety of high-dose Aflibercept in patients with diabetic macular edema.
Learn more.
Roche/Genentech (DOVETAIL)
A study of the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7200220 in monotherapy and in combination with Ranibizumab following intravitreal administration in patients with diabetic macular edema.
Learn more.
For more information about our
Retina Study,
call 267-541-3016
These technologies utilize different non-disease-causing viral vectors to carry and deliver a coding sequence for a soluble anti-VEGF protein. In essence, the goal is for anti-VEGF medication to be manufactured by cells in the eye, which will hopefully reduce the need for frequent intravitreal injections.
Adverum (INFINITY)
A study of the safety and efficacy of intravitreal ADVM-022 (AAV.7m8-Aflibercept) in subjects with diabetic macular edema.
Learn more.
These are studies to see If medications delivered by intravitreal injection, suprachoroidal injections, port delivery systems, or topical drops can slow down the progression of diabetic retinopathy or the effect of diabetes on the retinal blood vessels.
Kodiak (GLOW)
A prospective, randomized, double-masked, Sham-controlled, multi-center, two-arm, Phase 3 study to evaluate the efficacy and safety of intravitreal KSI-301 in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).
Learn more.
Boehringer Ingelheim Pharmaceuticals (BI 765128)
A study of BI 765128 in patients with diabetic macular ischemia who have received laser treatment for proliferative diabetic retinopathy.
Learn more.
Ocuterra (OTT166)
A study to evaluate the safety and efficacy of OTT166 ophthalmic solution in the treatment of diabetic retinopathy.
Learn more.
Port Delivery System (PDS): PDS is a small surgical implant that is intended to slowly release ranibizumab, a well-established anti-VEGF medication. The aim is to reduce the need for intravitreal injections and the implant can be refilled with a special syringe in the office setting.
Roche/Genentech (Pavilion)
A study of the efficacy, safety ,and pharmacokinetics of the port delivery system with Ranibizumab in patients with diabetic retinopathy.
Learn more.
Gene Therapy: These technologies utilize different non-disease-causing viral vectors to carry and deliver a coding sequence for a soluble anti-VEGF protein. In essence the goal is for anti-VEGF medication to be manufactured by cells in the eye, which will hopefully reduce the need for frequent intravitreal injections.
Regenxbio (ALTITUDE)
A study to evaluate the efficacy, safety, and tolerability of RGX-314 gene therapy delivered via single suprachoroidal space (SCS) injection in participants with diabetic retinopathy (DR) without center-involved diabetic macular edema.
Learn more.
For more information about our
Retina Study,
call 267-541-3016
Longer-Acting Pharmacologic Agents: These new medical compounds are being studied to determine their efficacy and safety in comparison to the current standard anti-vascular endothelial growth factor (VEGF) agents. Administered by intravitreal injection, they may potentially achieve a longer therapeutic effect.
Genentech (BALATON)
A study to evaluate the efficacy and safety of Faricimab in patients with macular edema secondary to branch retinal vein occlusion.
Learn more.
Genentech (COMINO)
A study to evaluate the efficacy and safety of Faricimab in patients with macular edema secondary to central or hemiretinal retinal vein occlusion.
Learn more.
Kodiak (BEACON)
A study to evaluate the efficacy and safety of intravitreal KSI-301 compared with intravitreal Aflibercept in participants with visual impairment due to treatment-naive macular edema secondary to retinal vein occlusion.
Learn more.
These are studies of gene therapies that target specific mutations found in certain inherited retinal diseases.
Atsena Therapeutics Inc. (SAR439483)
A study of subretinally injected SAR439483 administered in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D.
Learn more.
Ocugen (OCU400)*
A study to assess the safety and efficacy of OCU400 for retinitis pigmentosa associated with NR2E3 and RHO mutations.
Learn more.
*Pending
Iveric Bio (GATHER2)
A study to assess the safety and efficacy of intravitreal administration of Zimura (Complement C5 inhibitor) in patients with geographic atrophy (GA) secondary to age-related macular degeneration).
Learn more.
For more information about our
Retina Study,
call 267-541-3016
These are studies that assess the ability of intravitreal injections or systemic treatments to improve aspects of diseases that result in inflammation in the eye.
Roche/Genentech (DOVETAIL)
A study of the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7200220 in monotherapy and in combination with Ranibizumab following intravitreal administration in patients with diabetic macular edema.
Learn more.
NEI/NIH (ADVISE)
A study of the safety and efficacy of Adalimumab vs. conventional immunosuppression for uveitis.
Learn more.
For additional information, please see our FAQs page , call, or send a message below.
